Hepatitis B and inflammatory bowel disease: Role of antiviral prophylaxis

World Journal of Gastroenterology

Volumn 19, Issue 9, 2013, Pages 1342-1348

  López Serrano, Pilar ^a   Pérez Calle, Jose Lázaro ^a   Sánchez Tembleque, Maria Dolores ^b  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

Author keywords

Anti tumor necrosis factor; Hepatitis B virus; Immuno suppressants; Inflammatory bowel disease; Prophylaxis

Indexed keywords

ADEFOVIR; ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; RITUXIMAB; TELBIVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CROHN DISEASE; ENTERITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER DYSFUNCTION; NONHUMAN; PREVALENCE; PROPHYLAXIS; SCREENING; ULCERATIVE COLITIS; VIRUS REACTIVATION;

EID: 84875110401     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i9.1342     Document Type: Article

References (70)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219. [PMID: 22273662 DOI: 10.1016/ j.vaccine.2011.12.116]
2. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol 2012; 4: 74-80. [PMID: 22489259 DOI: 10.4254/wjh.v4.i3.74]
3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662. [PMID: 19714720 DOI: 10.1002/ hep.23190]
4. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 925-932. [PMID: 20480515 DOI: 10.1002/ibd.21284]
5. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63 Suppl 2: ii18-ii24. [PMID: 15479865 DOI: 10.1136/ard.2004.028209]
6. Loras C, Saro C, Gonzalez-Huix F, Mínguez M, Merino O, Gisbert JP, Barrio J, Bernal A, Gutiérrez A, Piqueras M, Calvet X, Andreu M, Abad A, Ginard D, Bujanda L, Panés J, Torres M, Fernández-Bañares F, Viver JM, Esteve M. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009; 104: 57-63. [PMID: 19098850 DOI: 10.1038/ajg.2008.4]
7. Chevaux JB, Bigard MA, Bensenane M, Oussalah A, Jarlot S, Belle A, Nani A, Bronowicki JP, Peyrin-Biroulet L. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol 2009; 33: 1082-1093. [PMID: 19896313 DOI: 10.1016/ j.gcb.2009.03.021]
8. Tolentino YF, Fogaca HS, Zaltman C, Ximenes LL, Coelho HS. Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital. World J Gastroenterol 2008; 14: 3201-3206. [PMID: 18506926 DOI: 10.3748/wjg.14.3201]
9. Biancone L, Pavia M, Del Vecchio Blanco G, D'Incà R, Castiglione F, De Nigris F, Doldo P, Cosco F, Vavassori P, Bresci GP, Arrigoni A, Cadau G, Monteleone I, Rispo A, Fries W, Mallardi B, Sturniolo GC, Pallone F. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001; 7: 287-294. [PMID: 11720317 DOI: 10.1097/00054725-200111000-00002]
10. Longo F, Hebuterne X, Tran A, Staccini P, Hastier P, Schneider S, Benzaken S, Tirtaine C, Rampal P. [Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors]. Gastroenterol Clin Biol 2000; 24: 77-81. [PMID: 10679588 DOI: GCB-01-2000-24-1-0399-8320-101019-ART54]
11. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 619-633. [PMID: 21416659 DOI: 10.1111/ j.1365-2036.2010.04570.x]
12. Park SH, Yang SK, Lim YS, Shim JH, Yang DH, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ, Kim JH. Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. Inflamm Bowel Dis 2012; 18: 2004-2010. [PMID: 22337144 DOI: 10.1002/ ibd.22905]
13. Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 2011; 17: 1531-1537. [PMID: 21472116 DOI: 10.3748/wjg.v17.i12]
14. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006; 4: 1076-1081. [PMID: 16861051 DOI: 10.1016/j.cgh.2006.05.027]
15. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539. [PMID: 17256718 DOI: 10.1002/hep.21513]
16. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188. [PMID: 1983820 DOI: 10.1007/s10620-006-9074-8]
17. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307. [PMID: 11055239 DOI: 10.1002/1096-9071(200011)62]
18. Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies. Blood Rev 2008; 22: 117-126. [PMID: 18343002 DOI: 10.1016/j.blre.2008.02.001]
19. Huang K, Hu JH, Wang HF, He WP, Chen J, Duan XZ, Zhang AM, Liu XY. Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol 2011; 17: 3448-3452. [PMID: 21876637]
20. Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, Cimino G, Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17: 3881-3887. [PMID: 22025876 DOI: 10.3748/wjg.v17.i34.3881]
21. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69. [PMID: 11187122]
22. Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol 2008; 83: 673-675. [PMID: 18528824 DOI: 10.1002/ajh.21214]
23. Hanbali A, Khaled Y. Incidence of hepatitis B reactivation following Rituximab therapy. Am J Hematol 2009; 84: 195. [PMID: 19140189 DOI: 10.1002/ajh.21343]
24. Beaugerie L, Gerbes AL. Liver dysfunction in patients with IBD under immunosuppressive treatment: do we need to fear? Gut 2010; 59: 1310-1311. [PMID: 20833661 DOI: 10.1136/ gut.2010.217331]
25. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis 1986; 6: 97-106. [PMID: 3529410 DOI: 10.1055/s-2008-1040593]
26. Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, Esteve M. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-1346. [PMID: 20577000 DOI: 10.1136/gut.2010.208413]
27. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365. [PMID: 15306601 DOI: 10.1136/gut.2004.040675]
28. Valle García-Sánchez M, Gómez-Camacho F, Poyato-González A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10: 701-702. [PMID: 15472541 DOI: 10.1097/0005472 5-200409000-00035]
29. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006; 12: 974-976. [PMID: 16521231]
30. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000; 223: 241-257. [PMID: 10719836 DOI: 10.1046/ j.1525-1373.2000.22335.x]
31. Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, Iwao Y, Saito H, Hibi T. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008; 43: 397-401. [PMID: 18592158 DOI: 10.1007/s00535-008-2165-x]
32. Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M, Kitadai Y, Yoshihara M, Sumii M, Chayama K. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50: 163-166. [PMID: 15712655]
33. Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009; 36: 1188-1194. [PMID: 19447932 DOI: 10.1007/s10620-005-1295-8]
34. Vermeire S, Van Assche G, Rutgeerts P. Vaccination and infection prevention in inflammatory bowel disease. F1000 Med Rep 2010; 2: 80. [PMID: 21170370]
35. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003; 30: 1624-1625. [PMID: 12858469 DOI: 10.1007/s10067-008-0950-9]
36. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, Claudepierre P. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31: 107-109. [PMID: 14705228]
37. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686-687. [PMID: 12810441 DOI: 10.1136/ard.62.7.686]
38. Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 20-34. [PMID: 19681818 DOI: 10.1111/j.1365-2036.2009.04112.x]
39. Toruner M, Loftus EV, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936. [PMID: 18294633 DOI: 10.1053/j.gastro.2008.01.012]
40. Garcia-Vidal C, Rodríguez-Fernández S, Teijón S, Esteve M, Rodríguez-Carballeira M, Lacasa JM, Salvador G, Garau J. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009; 28: 331-337. [PMID: 18797940 DOI: 10.1007/s10096-008-0628-x]
41. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007; 13: 1453-1454. [PMID: 17600380 DOI: 10.1002/ibd.20216]
42. Esteve M, Loras C, González-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007; 13: 1450-1451. [PMID: 17712837 DOI: 10.1002/ibd.20202]
43. Tanaka E, Urata Y. Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-α inhibitors. Hepatol Res 2012; 42: 333-339. [PMID: 22150950 DOI: 10.1111/j.1872-034X.2011.00937.x]
44. Montiel PM, Solis JA, Chirinos JA, a Casis B, Sánchez F, Rodríguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28: 718-720. [PMID: 18433400 DOI: 10.1111/j.1478-3231.2007.01665.x]
45. Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol 2010; 22: 494-499. [PMID: 20306568 DOI: 10.1097/MEG.0b013e328]
46. Matsumoto T, Marusawa H, Dogaki M, Suginoshita Y, Inokuma T. Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver Int 2010; 30: 1241-1242. [PMID: 20345703 DOI: 10.1111/j.1478-3231.2010]
47. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007; 13: 508-509. [PMID: 17206687 DOI: 10.1002/ibd.20035]
48. Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007; 11: 965-991. [PMID: 17981237 DOI: 10.1016/j.cld.2007.08.006]
49. Lledó JL, Fernández C, Gutiérrez ML, Ocaña S. Management of occult hepatitis B virus infection: an update for the clinician. World J Gastroenterol 2011; 17: 1563-1568. [PMID: 21472122]
50. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken) 2010; 62: 749-754. [PMID: 20535784]
51. Georgiadou SP, Zachou K, Liaskos C, Gabeta S, Rigopoulou EI, Dalekos GN. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int 2009; 29: 434-442. [PMID: 18694399 DOI: 10.1111/j.1478-3231.2008.01851.x]
52. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011; 46: 556-564. [PMID: 21246383 DOI: 10.1007/s00535-010-0367-5]
53. Cassano N, Mastrandrea V, Principi M, Loconsole F, De Tullio N, Di Leo A, Vena GA. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011; 25: 285-289. [PMID: 21880218 DOI: 10.1111/j.1365-4632.2011.05100.x]
54. Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol 2012; 36: 84-93. [PMID: 21920838 DOI: 10.1016/j.clinre.2011.07.018]
55. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008; 57: 549-558. [PMID: 18178610 DOI: 10.1136/ gut.2006.114660]
56. Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR, Vasiliauskas EA. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101: 1834-1840. [PMID: 16817843 DOI: 10.1111/j.1572-0241.2006.00646.x]
57. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, Domènech E, Eliakim R, Eser A, Frater J, Gassull M, Giladi M, Kaser A, Lémann M, Moreels T, Moschen A, Pollok R, Reinisch W, Schunter M, Stange EF, Tilg H, Van Assche G, Viget N, Vucelic B, Walsh A, Weiss G, Yazdanpanah Y, Zabana Y, Travis SP, Colombel JF. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91. [PMID: 21172250 DOI: 10.1016/j.crohns.2009.02.010]
58. Gandhi RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, Corcoran CP, Szczepiorkowski Z, Toner S, Cohen DE, Sax PE, Ukomadu C. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 2003; 36: 1602-1605. [PMID: 12802762 DOI: 10.1086/375084]
59. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242. [PMID: 19054588 DOI: 10.1016/j.jhep.2008.10.001]
60. Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, Cho SH, Han JY, Lee YS. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006; 43: 233-240. [PMID: 16440357 DOI: 10.1002/hep.21024]
61. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL, Chen PJ. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47: 844-853. [PMID: 18302293 DOI: 10.1002/hep.22106]
62. Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010; 116: 115-121. [PMID: 19899164 DOI: 10.1002/cncr.24742]
63. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008; 15: 89-102. [PMID: 18184191 DOI: 10.1111/j.1365-2893.2007.00902.x]
64. Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, Feld JJ. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012; 30: 3167-3173. [PMID: 22711851]
65. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749. [PMID: 14724827]
66. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2011; 34: 1145-1158. [PMID: 21978243]
67. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok AS, Manns M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, Janssen HL. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat 2011; 18 Suppl 1: 1-16. [PMID: 21824223 DOI: 10.1111/j.1365-2893.2011.01499]
68. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611. [PMID: 19075267 DOI: 10.1200/JCO.2008.18.0182]
69. Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcaraz P, Balandraud N, Thomachot B, Roudier J, Gérolami R. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009; 11: R179. [PMID: 19941642 DOI: 10.1186/ar2868]
70. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, Kamatani N, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Ochi T, Koike T. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 189-194. [PMID: 17644554 DOI: 10.1136/ard.2007.072967]